LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines

doi:10.16352/j.issn.1001-6325.2023.07.1023

Abstract

Abstract: Objective To dientify the correlation between the expression of long-chain non-coding RNA (lncRNA) RP11-686D22.10 and the survival of breast cancer patients, and to explore the effect of over-expression of RP11-686D22.10 on the proliferation and invasion of breast cancer cell lines. Methods The relationship between the expression level of RP11-686D22.10 and the survival time of breast cancer patients was analyzed with GEPIA database. The expression of RP11-686D22.10 in mammary epithelial cell line MCF-10A and breast cancer cell lines MCF7, SKBR3, HCC1937, BT549 and MB-MDA-468 was detected by real-time quantitative polymerase chain reaction (RT-qPCR). SKBR3 cell with the least expression of RP11-686D22.10 was selected and transfected with control plasmid (NC group) and RP11-686D22.10 over-expression plasmid (RP11-686D22.10 group). The proliferation and invasion of breast cancer cells were detected by CCK-8 and Transwell assays, respectively. The Linc2Go database predicted the targeting microRNA (miRNA) of RP11-686D22.10, and the dual-luciferase reporter gene assay was used to target at relationship between RP11-686D22.10 and miR-454-3p. The expression of miR-454-3p was detected by RT-qPCR. Western blot was used to detect the protein expression of Wnt/β-catenin signaling pathway. Results Compared with breast cancer patients with low expression of RP11-686D22.10, patients with high expression of RP11-686D22.10 had longer overall survival (P<0.01) and longer disease-free survival (P<0.01). The expression of RP11-686D22.10 in MCF7, SKBR3, HCC1937, BT549, and MB-MDA-468 cells was lower than that in MCF-10A cell (P<0.05). The expression of RP11-686D22.10 in SKBR3 cells was the lowest (P<0.01). Compared with the NC group, the proliferation ability of SKBR3 cells in the RP11-686D22.10 group was decreased (P<0.05), and the cell invasion ability was decreased (P<0.01). RP11-686D22.10 could target and bind miR-454-3p (P<0.01). Compared with the NC group, the expression of miR-454-3p in the RP11-686D22.10 group was decreased (P<0.01), and the expressions of Wnt/β-catenin signaling pathway proteins CCND1, β-catenin, JUN, AXIN2, and MMP2 was decreased. Conclusions The expression level of RP11-686D22.10 is closely related to the survival of breast cancer patients. Over-expression of RP11-686D22.10 inhibits the proliferation and invasion of breast cancer cell lines by targeting at miR-454-3p.

Key words: breast cancer, RP11-686D22.10, miR-454-3p, proliferation, invasion

CLC Number:

R737.14

TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines[J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.07.1023

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I7/1023

References

[1] Li X, Jin F, Li Y.A novel autophagy-related lncRNA prognostic risk model for breast cancer[J]. J Cell Mol Med, 2021, 25: 4-14.
[2] Pardini B, Dragomir MP.SCIRT lncRNA blocks the shot of breast cancer cells self-renewal mechanism[J]. Cancer Res, 2021, 81: 535-536.
[3] Li Y, Zhang M, Li F.LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN[J]. Histol Histopathol, 2020, 35: 1171-1180.
[4] Shen Y, Peng X, Shen C.Identification and validation of immune-related lncRNA prognostic signature for breast cancer[J]. Genomics, 2020, 112: 2640-2646.
[5] Zhao Z, Guo Y, Liu Y, et al. Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer[J]. Oncogene, 2021, 40: 4604-4614.
[6] Zhou J, Zhang S, Luo M.LncRNA PCAT7 promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway[J]. Future Oncol, 2021, 17: 701-710.
[7] Wu D, Zhu J, Fu Y, et al. LncRNA HOTAIR promotes breast cancer progression through regulating the miR-129-5p/FZD7 axis[J]. Cancer Biomark, 2021, 30: 203-212.
[8] Zhu L, Wang F, Fan W, et al. LncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis[J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53: 1198-1206.
[9] Han L, Yan Y, Zhao L, et al. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/WNT1 pathway[J]. J Cell Mol Med, 2020, 24: 6242-6252.
[10] Zhang S, Wang B, Xiao H, et al. LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p[J]. Thorac Cancer, 2020, 11: 1801-1816.
[11] Ouyang J, Liu Z, Yuan X, et al. LncRNA PRNCR1 promotes breast cancer proliferation and inhibits apoptosis by modulating microRNA-377/CCND2/MEK/MAPK axis[J]. Arch Med Res, 2021, 52: 471-482.
[12] Zong S, Dai W, Guo X, et al. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis[J]. Aging (Albany NY), 2021, 13: 23169-23181.
[13] Qian XL, Zhou F, Xu S, et al. miR-454-3p promotes oxaliplatin resistance by targeting PTEN in colorectal cancer[J]. Front Oncol, 2021, 11: 638537. doi: 10.3389/fonc.2021.638537.
[14] Shen G, Wu J, Mou Z, et al. miR-454-3p promotes of human glioma cell growth by targeting EGR3[J]. Exp Ther Med, 2019, 18: 4031-4039.
[15] Ren L, Chen H, Song J, et al. miR-454-3p-mediated Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis[J]. Theranostics, 2019, 9: 449-465.